The Cholera drugs in development market research report provides comprehensive information on the therapeutics under development for Cholera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cholera. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cholera and features dormant and discontinued products.

GlobalData tracks 17 drugs in development for Cholera by 16 companies/universities/institutes. The top development phase for Cholera is preclinical with four drugs in that stage. The Cholera pipeline has six drugs in development by companies and 11 by universities/ institutes. Some of the companies in the Cholera pipeline products market are: International Vaccine Institute, Boston Children’s Hospital and Tufts University.

The key targets in the Cholera pipeline products market include Cystic Fibrosis Transmembrane Conductance Regulator (ATP Binding Cassette Sub Family C Member 7 or Channel Conductance Controlling ATPase Camp Dependent Chloride Channel or ABCC7 or CFTR or EC 5.6.1.6), Cell Membrane, and Serine/Threonine Protein Kinase Pim (Pim Kinase or PIM or EC 2.7.11.1).

The key mechanisms of action in the Cholera pipeline product include Cystic Fibrosis Transmembrane Conductance Regulator (ATP Binding Cassette Sub Family C Member 7 or Channel Conductance Controlling ATPase Camp Dependent Chloride Channel or ABCC7 or CFTR or EC 5.6.1.6) Blocker with two drugs in Phase II. The Cholera pipeline products include two routes of administration with the top ROA being Oral and eight key molecule types in the Cholera pipeline products market including Live Attenuated Vaccine, and Small Molecule.

Cholera overview

Cholera is an acute infectious disease caused by a bacterium, Vibrio cholera, which results in a painless, watery diarrhea in humans. Symptoms of cholera can begin as soon as a few hours or as long as five days after infection. Symptoms are often mild, they can be very serious. Signs and symptoms of cholera include rapid heart rate, loss of skin elasticity, low blood pressure, thirst, and muscle cramps. If not treated, this can lead to shock and death in a matter of hours.

For a complete picture of Cholera’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.